Alebund Pharmaceuticals

Alebund Pharmaceuticals, established in Shanghai in 2018, is a clinical-stage biopharmaceutical company focused on creating therapies for kidney diseases and related chronic conditions. The company was co-founded by Dr. Gavin Xia and Jin Tian. Dr. Xia, who serves as Chairman and CEO, brings over 15 years of experience in the healthcare industry, including drug discovery and venture capital, and holds a PhD from the University of Chicago. The firm operates by discovering, developing, and commercializing a portfolio of drug candidates aimed at addressing significant unmet needs in the renal therapeutic space.

The company has strategically built a diversified pipeline of both small-molecule and biologic drug candidates. This pipeline targets a range of renal conditions, including chronic kidney disease (CKD) complications, IgA nephropathy (IgAN), diabetic kidney disease (DKD), and autosomal dominant polycystic kidney disease (ADPKD). A key focus is on hyperphosphatemia, a common complication for dialysis patients. Its lead asset, AP301, is an iron-based phosphate binder designed to lower serum phosphorus levels by binding to phosphate in the gastrointestinal tract. Another significant candidate is AP306, an oral inhibitor of phosphate transporters acquired from Chugai Pharmaceutical, which has received Breakthrough Therapy Designation from China's NMPA.

Alebund's business strategy involves advancing its drug candidates through clinical trials and toward commercialization. To support this, the company has secured significant funding, including a $60 million Series B round in May 2021, a $54.5 million Series B+ round in September 2021, and a RMB 550 million Series C financing in January 2025. These funds are allocated to advancing clinical programs, establishing manufacturing capabilities, and expanding its team. The company has completed the construction of a small molecule production facility in Yangzhou, China, and established a commercial team to handle the promotion of its products. By developing a portfolio of treatments, Alebund aims to provide comprehensive solutions for patients with kidney disease globally. Keywords: renal therapies, chronic kidney disease, biopharmaceutical, hyperphosphatemia, IgA nephropathy, diabetic kidney disease, drug development, phosphate binder, clinical stage, AP301, Gavin Xia, Jin Tian, CKD complications, dialysis, autosomal dominant polycystic kidney disease, ADPKD, small molecule drugs, biologics, AP306, renal medicine, nephrology, pharmaceutical manufacturing